Mono-methyl-HIST1H3A (K4) antibody is a specialized reagent designed to detect the mono-methylation state at lysine 4 (K4) of histone H3.1 (HIST1H3A), a core histone variant critical for chromatin structure and gene regulation. This modification is associated with enhancer regions and transcriptional activation, distinguishing it from di- (H3K4me2) and tri-methylated (H3K4me3) states linked to promoters and transcriptional elongation .
The specificity of anti-H3K4me1 antibodies is paramount due to overlapping epitopes and potential cross-reactivity. Below is a comparison of key commercial antibodies:
ab8895: Demonstrates consistent binding to mono-methylated K4 in Western blots (predicted band: 15 kDa; observed: 17–18 kDa) .
RM140: Exhibits strict specificity, confirmed by peptide array and ChIP assays .
ab8895:
RM140:
ab8895: Used at 1/100 dilution for 12 hours at 4°C in formaldehyde-crosslinked renal carcinoma cells .
RM140: 5 µg per ChIP assay in HeLa cells, validated via real-time PCR .
ab8895:
RM140:
A 2018 study (PMC6173622) highlighted systemic issues with H3K4 methylation antibodies, noting that low-specificity reagents often misclassify methylforms . For example:
ab8895: Polyclonal antibodies may exhibit variable epitope recognition .
RM140: Monoclonal antibodies reduce cross-reactivity but require rigorous peptide validation .
Blocking Buffers: 2% BSA for ab8895; 1% BSA/10% normal goat serum for IF .
Controls: Use parental cell lines (e.g., 786-O renal carcinoma) or peptide blocking to confirm specificity .
Enhancer Marking: H3K4me1 is enriched at enhancers, as shown in ChIP-seq data using high-specificity antibodies .
Transcriptional Regulation: H3K4me1 abundance correlates with tissue-specific gene expression, critical for cell identity .
Antibody Selection: Prioritize monoclonal antibodies (e.g., RM140) for methylform discrimination .
Validation: Include peptide blocking and methylated histone standards in experiments .
Data Interpretation: Cross-reference results with orthogonal methods (e.g., mass spectrometry) to mitigate antibody bias .